Health & Medicinearticle2026-11-10

Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial

Open access0 citations

Abstract

Remifentanil provides effective analgesia during invasive mechanical ventilation (IMV), but its utility is limited by opioid-related adverse events. Oliceridine, a G protein-biased μ-opioid receptor agonist, may decouple analgesia from these effects, but lacks evidence in critically ill patients. This multicentre, assessor- and patient-blinded, non-inferiority randomised controlled trial was conducted across 19 intensive care units (ICUs) in China. Adults receiving IMV were randomised 1:1 to oliceridine or remifentanil, titrated to a Critical-Care Pain Observation Tool score below 3. The primary endpoint was time in target analgesic range (TTR; non-inferiority margin −10%). Of 307 randomised patients, 304 comprised the modified intention-to-treat population (151 oliceridine, 153 remifentanil). Median TTR was 96.0% versus 92.3% (absolute difference 3.7%, 95% CI −0.3–5.7%). Oliceridine was associated with fewer mild-to-moderate adverse drug reactions (ADRs), occurring at 15.9 versus 22.2 events per 100 patient-days (IRR 0.72, 95% CI 0.52–1.00, P = 0.049), and a lower rate of respiratory depression during the study period (0% vs. 4.6%, P = 0.015). Post-extubation respiratory depression (0% vs. 7.9%, P = 0.005) and analgesic-sedation costs were both lower with oliceridine. IMV duration, ICU stay, and 28-day mortality did not differ. Subgroup analyses identified a nominal ADR benefit in patients with Acute Physiology and Chronic Health Evaluation II > 17 and a larger nominal TTR difference in those without acute respiratory distress syndrome. Oliceridine provides non-inferior analgesia to remifentanil with a more favourable respiratory safety profile and lower costs in critically ill adults. ClinicalTrials.gov NCT06454292 (registered June 11, 2024). In this multicentre randomised trial of 304 mechanically ventilated critically ill adults, oliceridine provided non-inferior analgesia to remifentanil with no post-extubation respiratory depression events (0% vs 7.9%) and numerically fewer mild-to-moderate adverse drug reactions and lower analgesic-sedation expenditure, supporting oliceridine as a promising analgesic alternative where respiratory safety during ventilator liberation is paramount.

// Source

View paper (DOI)Open access versionOpenAlexIntensive Care MedicinePublished 2026-11-10

Authors: Sen Lu, Jun Luo, Qiang Li, Lei Xian-ying, Xuefeng Ding, Xuefeng Ding, Qionghua Hu, Qiong Hua Hu, Xue Zhang, Lili Duan, Sheng Lv, Qi-fang Ran, 冉启芳, Chuan Guo, Jian-jun Dong, Yu-qi Yang, Li Xu, Jin Yang, Jin Yang, Li-fei Qiu, Ben-cai Jing, Feng-juan Jia, Li Zhang, Qi-Bing Tang, Miguel Ibarra-Estrada, Minghao Luo, Chun Pan, 黄晓波, Ignacio Martín‐Loeches

Institutions: Zigong First People's Hospital, Sichuan University, University of Oxford, First Affiliated Hospital of Chengdu Medical College, Third People's Hospital of Chengdu, Universidad de Guadalajara, Affiliated Hospital of North Sichuan Medical College, Cambridge University Hospitals NHS Foundation Trust, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Hospital Civil de Guadalajara, Trinity College Dublin, Chengdu Second People's Hospital, Affiliated Hospital of Southwest Medical University, Southwest Medical University, Addenbrooke's Hospital, Panzhihua Central Hospital, Mianyang Third People's Hospital, St. James's Hospital, The First People's Hospital of Neijiang, The First People's Hospital of Guangyuan, Instituto Jalisciense de Cancerología